RUNX3 inhibits the invasion and migration of esophageal squamous cell carcinoma by reversing the epithelial-mesenchymal transition through TGF-β/Smad signaling

ZHAOHUA XIAO1,2, YU TIAN2, YANG JIA1, QI SHEN1, WENPENG JIANG1, GANG CHEN1, BIN SHANG1, MO SHI1, ZHOU WANG1 and XIAOGANG ZHAO2,3*

1Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021; 2Department of Thoracic Surgery, The Second Hospital of Shandong University; 3Key Laboratory of Thoracic Cancer in Universities of Shandong, Jinan, Shandong 250033, P.R. China

Received July 22, 2019; Accepted January 29, 2020

DOI: 10.3892/or.2020.7508

Abstract. Runt-related transcription factor 3 (RUNX3) is a candidate tumor suppressor, and its inactivation may play a crucial role in the carcinogenesis process of numerous cancer types, including esophageal squamous cell carcinoma (ESCC). We previously revealed that RUNX3 inactivation was correlated with lymph node metastasis (LNM) and ESCC recurrence. However, the exact mechanisms of this process are still under investigation. The aim of the present study was to examine the potential roles and underlying molecular mechanisms of RUNX3 in ESCC metastasis and the epithelial-mesenchymal transition (EMT). According to the results, RUNX3 expression in ESCC tissue was significantly reduced compared with that in adjacent normal tissue (0.50±0.20 vs. 0.83±0.16; P<0.001). In addition, statistical analysis revealed a close association between decreased RUNX3 expression and T status (P=0.027) and LNM (P=0.017) in ESCC patients. Pearson’s correlation coefficient analysis was then used to evaluate correlations between RUNX3 and EMT-related marker expression. The results revealed that RUNX3 expression in ESCC tissues was negatively correlated with the expression of N-cadherin (r=-0.429; P<0.01) and Snail (r=-0.364; P<0.01) and positively correlated with the expression of E-cadherin (r=0.580; P<0.01). Moreover, Eca109 and EC9706 cell invasion, migration, MMP-9 expression and EMT were significantly inhibited by RUNX3 overexpression. Notably, further analysis revealed that RUNX3 overexpression markedly inhibited the phosphorylation of Smad2/3; RUNX3-overexpressing cells also displayed less sensitivity to TGF-β1-induced EMT than control cells. Thus, RUNX3 may inhibit the invasion and migration of ESCC cells by reversing EMT through TGF-β/Smad signaling and may be useful as a therapeutic target.

Introduction

With approximately 442,000 new cases diagnosed and 440,000 associated deaths worldwide in 2013, esophageal carcinoma is ranked as the eighth most common human malignancy and the sixth leading cause of cancer-related deaths worldwide (1). Esophageal squamous cell carcinoma (ESCC), as the predominant histopathological type, accounts for approximately 90% of esophageal cancer cases (2). Despite advances in diagnosis and multimodal therapy, the prognosis remains less than satisfactory, with 5 year overall survival rates ranging between 15 and 50% (3-5). Lymph node metastasis (LNM) is the single most important prognostic factor and remains the major cause of mortality after complete resection in ESCC patients (6,7). In fact, it has been revealed that the number of metastatic nodes is closely related to survival, and the 5 year survival rate of patients with 0, 1-2, ≥3 positive lymph nodes was 59.8%, 33.4% and 9.4%, respectively (3). Overall, there is an urgent need to elucidate the underlying mechanisms of LNM by identifying key molecules that may contribute to the development of reasonable treatment plans for different patients and improve the outcomes of ESCC patients.

Runt-related transcription factor 3 (RUNX3), located on human chromosome 1p36.1, is a member of the runt-domain family of transcription factors (8,9). RUNX3 has been...
identified as a potential tumor suppressor gene in a variety of malignancies, especially in gastrointestinal cancers, such as gastric cancer, hepatocellular cancer, colorectal cancer, and ESCC (8,10-13). RUNX3 inactivation is involved in tumor development and metastasis through different processes, including the cell cycle, apoptosis, angiogenesis, EMT, invasion and migration (14). Although researchers have investigated the expression profile and roles of RUNX3 in ESCC progression (15), the molecular mechanisms of RUNX3 in EMT and ESCC metastasis have not yet been investigated and need to be elucidated.

Tumor metastasis is a multacellular process that involves cell-cell adherence, invasion, migration, angiogenesis, extracellular matrix (ECM) degradation and EMT (16,17). Among these processes, EMT is thought to have crucial functions. EMT is a dynamic process in which epithelial cells typically lose their epithelial characteristics, including cell polarity and cell-cell contact, and acquire a spindle shape migration phenotype (18,19). In addition, the expression of the epithelial markers E-cadherin and claudin-1 is reduced, whereas that of the mesenchymal markers N-cadherin and vimentin is increased (20).

The transforming growth factor β (TGF-β) pathway plays a complex dual role in tumor development. It acts as a tumor suppressor pathway during the early stages of epithelial neoplasia by inhibiting tumor cell proliferation and inducing apoptosis. At later stages of carcinogenesis, TGF-β signaling contributes to tumor invasion and metastasis by inducing EMT (18,21,22). TGF-β/Smad signaling, the main pathway in EMT, is initiated by transforming growth factor β1 (TGF-β1) binding to its type II receptor (TβRII). TβRII forms a heterodimer with the TGF-β type I receptor (TβRI); activated TβRII phosphorylates R-Smad (Smad2 and Smad3) at the distal C-terminal SXS motif, after which pSmad2/3 and Co-Smad (Smad4) form a transcription complex that transduces the signal to the nucleus. In the nucleus, the Smad complex directly or indirectly binds to various transcription factors, thus providing additional regulation of target genes that mediate EMT (23-25).

On the basis of our previous studies, the aim of the present study was to investigate the potential roles and molecular mechanisms of RUNX3 in ESCC metastasis and EMT.

Materials and methods

Ethics statement. The present study was approved by the Research Ethics Committee of Shandong Provincial Hospital Affiliated with Shandong University. Written informed consent for use of the tissues and data analysis was obtained from every patient or their relatives.

Patients and specimens. In total, 102 ESCC tissues and 30 adjacent normal tissues (>5 cm from the margin of the tumor) were harvested from patients who underwent Ivor-Lewis esophagectomy with two-field lymphadenectomy at the Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University from May 2017 to December 2018. All patients underwent esophagectomy with complete resection, and none received neoadjuvant radio-/chemotherapy. Postoperative staging was based on the eighth edition of the International Union Against Cancer (UICC) tumor-node-metastasis (TNM) classification criteria published in 2017. Among the 102 ESCC patients, 45 had LNM, and 57 did not have LNM. The detailed clinical data for these patients are presented in Table I.

Cell culture and transfection. Five human ESCC cell lines (TE-1, Eca109, KYSE150, KYSE450, and EC9706) were purchased from the Cell Bank of the Shanghai Institute in China. All cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). For activation of the TGF-β pathway, cells were treated with 10 ng/ml recombinant TGF-β1 (cat. no. AF-100-21C-10; PeproTech, Inc.). Cell culture plates were maintained at 37˚C in a humidified 5% CO2 incubator. Human RUNX3 overexpression plasmids (NM-004350) were chemically synthesized and packaged into lentiviruses (Shanghai GeneChem Co., Ltd.). Puromycin was used at 5 μg/ml for 1 week to select stably transfected cells. Cells were labeled BC (without lentivirus transfection), vector (transfected with the control vector), and RUNX3 (transfected with the RUNX3 overexpression plasmid).

Immunohistochemical (IHC) analysis. IHC analysis was performed to detect the expression level of RUNX3 as well as the correlation between the expression of RUNX3 and EMT-related markers using the streptavidin-peroxidase (SP) method. Sections were stained with anti-RUNX3 antibodies at 4˚C overnight. The primary antibodies were as follows: anti-RUNX3 (dilution 1:100; cat. no. ab40278), anti-N-cadherin (dilution 1:100; cat. no. ab76011), and anti-Snail (dilution 1:1,000; cat. no. ab40278), anti-N-cadherin (dilution 100; cat. no. ab180714; all from Abcam), and anti-E-cadherin (dilution 1:100; cat. no. 20874-1-AP; ProteinTech Group, Inc.) antibodies at 4˚C overnight. The primary antibodies were replaced with phosphate-buffered saline (PBS) as a negative control to rule out nonspecific binding. The secondary antibody and avidin-biotin peroxidase complex methods were performed according to the standard protocols provided by the manufacturer (ZSGB Biotech Beijing; OriGene technologies, Inc.). All sections were evaluated by two pathologists who were blinded to the clinical data.

Western blot analysis. Protein was extracted from tissue samples and tumor cells using radioimmunoprecipitation (RIPA) lysis buffer (Beyotime Institute of Biotechnology), and the concentration was determined using a bichinchoninic acid (BCA) kit. Equal amounts of protein (30 μg) were separated by 8% or 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Briefly, 5% nonfat dry milk was used to block nonspecific binding. The membranes were incubated overnight at 4˚C with primary antibodies. Following three washes, the membranes were incubated with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (dilution 1:5,000; goat anti-mouse cat. no. ZB-2305 and goat anti-rabbit cat. no. ZB-2301; both from ZSGB Biotech) for 1 h at room temperature. Finally, the protein levels were quantified using an enhanced chemiluminescence (ECL) detection system (Amersham imager 600; General Electric). The antibodies used in the present study were as follows: anti-RUNX3 (dilution 1:500; cat. no. ab40278), anti-N-cadherin (dilution 1:1,000; cat. no. ab76011), and anti-Snail (dilution 1:1,000;
Table I. Correlations between RUNX3 expression and clinicopathological features of 102 ESCC patients.

| Parameters          | Cases (n=102) | Positive (n=23) | Negative (n=79) | P-value |
|---------------------|---------------|-----------------|-----------------|---------|
| Sex                 |               |                 |                 |         |
| Male                | 45            | 12 (26.7)       | 33 (73.3)       | 0.475   |
| Female              | 57            | 11 (19.3)       | 46 (80.7)       |         |
| Age (years)         |               |                 |                 |         |
| ≤50                 | 41            | 10 (24.4)       | 31 (75.6)       | 0.810   |
| >50                 | 61            | 13 (21.3)       | 48 (78.7)       |         |
| Tumor size (cm)     |               |                 |                 |         |
| <3                  | 44            | 12 (27.3)       | 32 (72.7)       | 0.347   |
| ≥3                  | 58            | 11 (19.0)       | 47 (81.0)       |         |
| T status            |               |                 |                 |         |
| T1-2                | 63            | 19 (30.2)       | 44 (69.8)       | 0.027   |
| T3-4                | 39            | 4 (10.3)        | 35 (89.7)       |         |
| Differentiation degree |           |                 |                 | 0.158   |
| Low                 | 54            | 9 (16.7)        | 45 (83.3)       |         |
| Mid-high            | 48            | 14 (29.2)       | 34 (70.8)       |         |
| LNM                 |               |                 |                 | 0.017   |
| No                  | 57            | 18 (31.6)       | 39 (68.4)       |         |
| Yes                 | 45            | 5 (11.1)        | 40 (88.9)       |         |

Bold values indicate P<0.05. ESCC, esophageal squamous cell carcinoma; RUNX3, runt-related transcription factor 3; LNM, lymph node metastasis.

Results

RUNX3 expression is decreased in ESCC. The expression profile of RUNX3 in 30 pairs of ESCC tumor tissues and adjacent normal tissues was first assessed with IHC analysis. Significant staining was readily observed in the nuclei of the
noncancerous tissue; weak immunostaining was observed in tumor cells (Fig. 1). Furthermore, RUNX3 expression levels were verified through western blot analysis and it was revealed that RUNX3 expression in tumor tissues was significantly lower than that in adjacent normal tissues (Fig. 2A and B; RUNX3/GAPDH: 0.50±0.20 vs. 0.83±0.16; *P*<0.001).

**RUNX3 expression is associated with T status and LNM.** Tissues were considered RUNX3-negative when nuclear staining was present in <5% of the cells, with or without cytoplasmic staining. According to these criteria, all 102 ESCC patient samples were divided into two groups: 23 cases (22.55%) were categorized as the positive expression group, and 79 cases (77.45%) were categorized as the negative expression group. The chi-square test was next used to investigate the relationship between RUNX3 expression and clinicopathological parameters (including age, sex, tumor size, T status, differentiation degree, and LNM). As revealed in Table I, negative RUNX3 expression was more common in T3-4 than in T1-2 cases (89.7% vs. 69.8%, respectively; *P*=0.027) and more prevalent in node-positive than in node-negative cases (88.9% vs. 68.4%, respectively; *P*=0.017). Thus, it was surmised that decreased RUNX3 expression may play a vital role in ESCC metastasis. No significant differences were revealed between RUNX3 expression and other clinicopathological parameters.

**RUNX3 expression is negatively correlated to Snail and N-cadherin expression and positively correlated to E-cadherin expression in ESCC tissues.** EMT has been reported to contribute to tumor invasion, migration and metastasis in various cancers (27). To elucidate the mechanisms of RUNX3 in ESCC LNM, the correlation between RUNX3 and EMT-related marker expression in LNM tissues and non-LNM tissues (Fig. 1) was evaluated. IHC results revealed RUNX3 expression to be negatively correlated to the expression of the mesenchymal marker N-cadherin (*r*=-0.429; *P*<0.001) and transcription factor Snail (*r*=-0.364; *P*<0.01) and
positively correlated to the expression of the epithelial marker E-cadherin \( (r=0.580; \ P<0.01) \) in ESCC tissues (Table II). These results indicated that RUNX3 expression was associated with ESCC EMT.

**Cell transfection.** The expression levels of RUNX3 in five ESCC cell lines were detected via qRT-PCR and western blot analyses. According to the results, Eca109 and EC9706 cells exhibited the lowest expression of RUNX3 at both the protein (Fig. 3A) and mRNA (Fig. 3B) levels. Thus, Eca109 and EC9706 cells were used to analyze the upregulation of RUNX3 expression. Compared with the blank control and vector groups, the RUNX3 group exhibited significantly upregulated RUNX3 expression, although there was no difference in RUNX3 expression between the blank control and vector groups (Fig. 3C and D).

Table II. Correlations between expressions of RUNX3 and EMT related markers in 102 ESCC patients.

| Parameters | E-cadherin | N-cadherin | Snail |
|------------|------------|------------|-------|
|            | Positive   | Negative   | Positive | Negative | Positive | Negative |
| RUNX3       |            |            |         |           |         |           |
| Positive    | 17         | 6          | 7       | 16        | 11      | 12        |
| Negative    | 10         | 69         | 62      | 17        | 67      | 12        |
| r           | 0.580      | -0.429     | -0.364  |           |         |           |
| P-value     | <0.01      | <0.01      | <0.01   |           |         |           |

RUNX3, runt-related transcription factor 3; EMT, epithelial-mesenchymal transition; ESCC, esophageal squamous cell carcinoma.
Upregulation of RUNX3 significantly decreases the invasion and migration abilities of ESCC cells as well as MMP-9 expression. Since RUNX3 expression was negatively correlated with T status and LNM in ESCC patients, the effect of RUNX3 on cell migration and invasion in ESCC cells was further investigated using wound-healing and Transwell assays. In the Transwell assays, the number of cells in the RUNX3 group that traversed the membrane was significantly decreased compared with that in the vector group (Fig. 4A and B; P<0.01). Moreover, the number of cells that invaded Matrigel was also significantly attenuated in the RUNX3 group (Fig. 4C and D; P<0.01). The data from the wound-healing assay further supported this finding, as upregulating expression of RUNX3 suppressed cell migration compared with the vector group (Fig. 4E). Furthermore, restoration of RUNX3 expression led to a significant decrease in the expression of MMP-9 (Fig. 4F and G; P<0.01), which can promote invasion and LNM through ECM degradation (28).

Upregulation of RUNX3 may reverse EMT and decrease Smad2/3 phosphorylation in ESCC cells. To evaluate the mechanism of RUNX3 in ESCC metastasis, the levels of EMT markers (E-cadherin, N-cadherin and Snail) were detected by western blotting and it was revealed that N-cadherin and Snail expression levels were downregulated in RUNX3-overexpressing cells but that E-cadherin expression was significantly upregulated (Fig. 5A). TGF-β/Smad-induced EMT has been suggested to be associated with the development and progression of ESCC. To further assess whether RUNX3 reverses ESCC EMT through the TGF-β/Smad pathway, the levels of Smad2, Smad3 and their phosphorylated versions (pSmad2, pSmad3) were evaluated. The results of the western blot analysis revealed that levels of both pSmad2 and pSmad3 were decreased in the RUNX3 group compared to the vector group; in contrast, the levels of Smad2 and Smad3 were unaltered (Fig. 5B). Immunofluorescence assays were also used to validate the effect of RUNX3 overexpression on pSmad2 and pSmad3 staining, and as revealed in
RUNX3-overexpressing cells display diminished responsiveness to TGF-β1-induced EMT. A previous study indicated that Runx3-null gastric epithelial lines are unexpectedly sensitive to TGF-β1-induced EMT (29). The sensitivity of RUNX3 to TGF-β1-induced EMT was next investigated and it was revealed that the levels of pSmad2/3 peaked at 1 h after TGF-β treatment (Fig. 6A and B). Thus, the temporal pattern of Smad2/3 phosphorylation after treatment with 10 ng/ml TGF-β1 for 1 h was investigated. Based on the results, the levels of pSmad2/3 significantly increased in the vector group, whereas no significant changes were evident in RUNX3-overexpressing cells (Fig. 7A). The expression of EMT-related markers after 72 h of stimulation with TGF-β1 was also assessed. TGF-β1-induced increases in N-cadherin and Snail and decreases in E-cadherin levels were significantly greater in the vector control cells than in the RUNX3-overexpressing cells (Fig. 7B). One hallmark of EMT is phenotypic change in epithelial cell morphology. Eca109 and EC9706 cells displayed an elongated fibroblast-like morphology and reduced cell-cell contact after 72 h of TGF-β1 stimulation, whereas noticeable morphological changes and cell-cell contact were not detected in RUNX3-overexpressing cells (Fig. 7C and D).

Discussion

It is widely accepted that surgery is the standard treatment for patients with localized ESCC (30). Although surgical treatment can cure 90% of patients with early ESCC, the prognosis is suboptimal for advanced-stage ESCC due to a lack of early diagnosis methods, local relapse, distant metastasis and resistance to traditional treatments such as chemotherapy and radiotherapy. The esophagus has a unique histological structure involving a rich lymphatic-capillary network in the submucosa, which contributes to variable lymphatic spread and skip metastasis (3,31). In fact, Li et al reported that approximately 33.1% of ESCC patients experience LNM when the submucosa (T1b) is invaded and that 4.3% of ESCC patients still experience LNM even when the tumor is confined to the mucosa (T1a) (31). We previously demonstrated that RUNX3 expression was significantly related to LNM and that RUNX3 inactivation was predictive of poor survival (32). In the present study, we focused on exploring the underlying mechanisms of RUNX3-mediated EMT and metastasis.

According to the present results, RUNX3 expression was markedly lower in tumor tissues than in adjacent normal tissues, and this decreased expression of RUNX3 was correlated with T status and LNM in ESCC patients. In an attempt to validate the biological function of RUNX3 in ESCC, Fig. 5C, pSmad2 and pSmad3 staining was markedly decreased in the RUNX3 group.

RUNX3-overexpressing cells display diminished responsiveness to TGF-β1-induced EMT. A previous study indicated that Runx3-null gastric epithelial lines are unexpectedly sensitive to TGF-β1-induced EMT (29). The sensitivity of RUNX3 to TGF-β1-induced EMT was next investigated and it was revealed that the levels of pSmad2/3 peaked at 1 h after TGF-β treatment (Fig. 6A and B). Thus, the temporal pattern of Smad2/3 phosphorylation after treatment with 10 ng/ml TGF-β1 for 1 h was investigated. Based on the results, the levels of pSmad2/3 significantly increased in the vector group, whereas no significant changes were evident in RUNX3-overexpressing cells (Fig. 7A). The expression of EMT-related markers after 72 h of stimulation with TGF-β1 was also assessed. TGF-β1-induced increases in N-cadherin and Snail and decreases in E-cadherin levels were significantly greater in the vector control cells than in the RUNX3-overexpressing cells (Fig. 7B). One hallmark of EMT is phenotypic change in epithelial cell morphology. Eca109 and EC9706 cells displayed an elongated fibroblast-like morphology and reduced cell-cell contact after 72 h of TGF-β1 stimulation, whereas noticeable morphological changes and cell-cell contact were not detected in RUNX3-overexpressing cells (Fig. 7C and D).
Figure 5. Upregulation of RUNX3 reverses EMT and decreases Smad2/3 phosphorylation in ESCC cells. (A) Western blot results revealed that expression of E-cadherin was increased and that expression of N-cadherin and Snail was decreased in the RUNX3 group compared with the vector group. (B) The expression levels of pSmad2/3 were decreased with RUNX3 overexpression. (C) Eca109 and EC9706 cells were subjected to immunofluorescence staining with an anti-pSmad2 or -pSmad3 antibody. Vector, vector group; RUNX3, RUNX3 group. RUNX3, runt-related transcription factor 3; EMT, epithelial-mesenchymal transition; ESCC, esophageal squamous cell carcinoma.

Figure 6. TGF-β1 activates Smad2/3 phosphorylation. (A) ESCC cells were treated with 10 ng/ml TGFβ1 for 0, 0.25, 0.5, 1, and 2 h, and western blotting was performed to analyze Smad2/3 phosphorylation. (B) Relative pSmad2/3 levels were quantified using Graph Prisim 6 software. TGF-β1 causes time-dependent phosphorylation of Smad2/3, and the levels of pSmad2/3 peaked at 1 h after TGF-β1 treatment. TGF-β1, transforming growth factor β1; ESCC, esophageal squamous cell carcinoma; pSmad2/3, phosphorylated Smad2/3.
metastasis, Eca109 and EC9706 cells were transfected with a RUNX3-expressing lentivirus and it was revealed that restoration of RUNX3 expression attenuated invasion and migration abilities. Moreover, RUNX3 overexpression led to a significant decrease MMP-9 expression. All of these results indicated that RUNX3 markedly inhibited ESCC cell metastasis. Since EMT plays an important role in tumor invasion and metastasis, it was surmised that RUNX3 may prevent ESCC cell metastasis by modulating EMT. The expression levels of E-cadherin were determined to be increased and those of Snail and N-cadherin to be decreased in the RUNX3-overexpressing group compared with the vector control group. IHC results also revealed that RUNX3 expression was positively correlated with E-cadherin expression and inversely with Snail and N-cadherin expression in ESCC tissues, which strongly supports our hypothesis.

Recently, an accumulating number of studies have demonstrated that EMT can be induced by numerous molecules, such as inflammatory cytokines, growth factors and numerous transcription factors (20). Among these factors, TGF-β is a key driver of EMT (19). Cumulative research has revealed that TGF-β signaling is tightly controlled by the phosphorylation of R-Smads and that dephosphorylation of R-Smads disrupts signal relay (33). Lin et al reported that PPM1A dephosphorylates TGF-β-activated Smad2/3, dissociates the Smad complex, and promotes the nuclear export of Smad2/3 (34). RUNX3, as a critical downstream effector in the TGF-β signaling pathway, physically interacts with R-Smad through its C-terminal region (35-38). In this study, it was revealed that RUNX3 overexpression resulted in significant dephosphorylation of pSmad2/3, indicating that the effect of RUNX3 on reversing EMT may be attributable, at least in part, to TGF-β/Smad signaling.

A previous study has indicated that the gastric mucosa of Runx3-null mice is resistant to TGF-β1-induced growth suppression (8). However, in another study, Voon et al reported that Runx3-null gastric epithelial lines were unexpectedly sensitive to TGF-β1-induced EMT (29). Therefore, the sensitivity of RUNX3 to TGF-β1-induced EMT was further assessed. Upon TGF-β1 stimulation, significantly decreased levels of E-cadherin and increased levels of N-cadherin, Snail and pSmad2/3 were observed in the vector group. However, no effect on these proteins was observed in the RUNX3 group. Morphological studies also revealed that TGF-β1 treatment induced phenotypic changes, resulting in the cells in the vector group adopting a more spindle-like morphology than the cells in the RUNX3 group, which indi-
icates that RUNX3-overexpressing ESCC cells were resistant to TGF-β1-induced EMT.

RUNX3 is thought to exist in a basal, inactive state in the cytoplasm and cannot act as a transcription factor (9). Increasing evidence indicates that RUNX3 can be reactivated and is therefore considered to be a good drug target (39). Our previous studies demonstrated that reactivation of RUNX3 by 5-azacytidine (an anticancer drug) inhibited the malignant behavior of ESCC cells (40). Moreover, heterologous RUNX3 expression was able to reverse cisplatin resistance in ESCC cell lines (41). In the present study, evidence is provided that restoration of RUNX3 expression decreased the invasion and migration of ESCC cells by inhibiting EMT. Collectively, the present results revealed that novel drugs targeting RUNX3 are a promising treatment strategy for ESCC.

There are several limitations to the present study. Firstly, the number of samples was relatively small, which may affect the reliability of our findings. Therefore, larger sample sizes and multicenter randomized studies are required. Secondly, the cells were not serum-starved in the wound-healing assay. In our future studies, we will attempt to knock down RUNX3 and develop a lung metastasis model to further validate our results in vivo. Immunoprecipitation assays will also be performed to verify the binding of RUNX3 to R-Smad.

In summary, in the present study it was revealed that RUNX3 inhibited EMT by abrogating TGF-β1-mediated Smad2/3 phosphorylation and decreasing the expression of the transcription factor Snail, thereby inhibiting the invasion and migration abilities of ESCC cells. This study is the first to elucidate the detailed mechanisms of RUNX3-mediated regulation of EMT and metastasis in ESCC. The findings herein support the hypothesis that targeted therapies for RUNX3 may serve as complementary treatment approaches to control postoperative LNM and improve the survival of ESCC patients.

Acknowledgements

The authors appreciate the help from the Departments of Thoracic Surgery and Pathology of Shandong Provincial Hospital affiliated to Shandong University and the Department of Thoracic Surgery of The Second Hospital of Shandong University.

Funding

The present study was funded by the Natural Science Foundation of Shandong Province (grant no. ZR2017MH089), and the Major Program of Shandong Province Natural Science Foundation (grant no. ZR2018ZC0232).

Availability of data and materials

The data used during the study are available from the corresponding author upon reasonable request.

Authors’ contributions

YT and QS collected the samples and acquired the experimental data. WJ, GC and MS performed the analysis of the data. ZX wrote the manuscript. ZX, YT, YJ and BS performed the experiments. ZW and XGZ designed, supervised and funded the experiments. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The present study was approved by the Research Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University (protocol no. 2017550). Written informed consent was obtained from each patient or their relatives for use of the tissues and data analysis.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al: The global burden of cancer 2013. JAMA Oncol 1: 505-527, 2015.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
3. Ji X, Cai J, Chen Y and Chen LQ: Lymphatic spreading and lymphadenectomy for esophageal carcinoma. World J Gastrointest Surg 8: 90-94, 2016.
4. Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet 381: 400-412, 2013.
5. Rutegard M, Charonis K, Lu Y, Lagergren P, Lagergren J and Rouvelas I: Population-based esophageal cancer survival after resection after neoadjuvant therapy: An update. Surgery 152: 903-910, 2012.
6. Liu Q, Cai XW, Wu B, Zhu ZF, Chen HQ and Fu XL: Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: Implications for the clinical target volume design of postoperative radiotherapy. PLoS One 9: e97225, 2014.
7. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JH, Holscher A, Law S, Ruoel A, Ancona E, Griffin SM, Altorki NK, et al: Predicting systemic disease in patients with esophageal cancer after esophagectomy: A multinational study on the significance of the number of involved lymph nodes. Ann Surg 248: 979-985, 2008.
8. Chi XZ, Yang JQ, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor β (α)-activated SMAD. Mol Cell Biol 25: 8097-8107, 2005.
9. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005.
10. Hiramatsu T, Osaki M, Ito Y, Tanji Y, Tokuyasu N and Ito H: Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology 72: 316-324, 2005.
11. Shirahara H, Nishina S and Yamamoto K: Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem 112: 745-749, 2011.
12. Soong R, Shah N, Peh BK, Chong PY, Ng SS, Zeps N, Joseph D, Salto-Tellez M, Iacopetta B and Ito Y: The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer 100: 676-679, 2009.
13. Sugiuira H, Ishiguro H, Kuwabara Y, Kimura M, Mitsu A, Mori Y, Ogawa R, Katada T, Harata K and Fujiy I: Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 19: 713-719, 2008.
14. Chen F, Liu X, Bai J, Pei D and Zheng J: The emerging role of RUNX3 in cancer metastasis (Review). Oncol Rep 35: 1227-1236, 2016.

15. Torquati A, O’Rear L, Longobardi L, Spagnoli A, Richards WO and Daniel Beauchamp R: RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 136: 310-316, 2004.

16. Guan X: Cancer metastases: Challenges and opportunities. Acta Pharm Sin B 5: 402-418, 2015.

17. Yilmaz M, Christofori G and Lehembre F: Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 13: 535-541, 2007.

18. Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, Fukamachi H and Ito Y: Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138: 255-265, 2010.

19. Xu J, Lamouille S and Derynck R: TGF-Beta-Induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.

20. Mittal V: Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol 13: 395-412, 2018.

21. Foroutan M, Cursons J, Hediyeh-Zadeh S, Thompson EW and Davis MJ: A transcriptional program for detecting TGFβ-induced EMT in cancer. Mol Cancer Res 15: 619-631, 2017.

22. Ikushima H and Miyazono K: TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer 10: 415-424, 2010.

23. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.

24. Miyazono K, Suzuki H and Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 94: 230-234, 2003.

25. Wrighton KH, Lin X and Feng XH: Phospho-control of TGF-beta superfamily signaling. Cell Res 19: 8-20, 2009.

26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

27. Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol 29: 212-226, 2019.

28. Xia T, Song S, Fan K, Zhai W, Fang B, Wang SH and Wang JJ: XBPI induces MMP-9 expression to promote proliferation and invasion in human esophageal squamous cell carcinoma. Am J Cancer Res 6: 2031-2040, 2016.

29. Voon DC, Wang H, Koo JK, Nguyen TA,Hor YT, Chu YS, Ito K, Fukamachi H, Chan SL, Thiery JP and Ito Y: Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells 30: 2088-2099, 2012.